GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Debt-to-Revenue

Apures Co (XKRX:149300) Debt-to-Revenue : 9.47 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Apures Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,610.4 Mil. Apures Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,632.0 Mil. Apures Co's annualized Revenue for the quarter that ended in Dec. 2023 was ₩658.9 Mil. Apures Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 9.47.


Apures Co Debt-to-Revenue Historical Data

The historical data trend for Apures Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Debt-to-Revenue Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.77 29.68 9.17 10.96 9.47

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.77 29.68 9.17 10.96 9.47

Competitive Comparison of Apures Co's Debt-to-Revenue

For the Diagnostics & Research subindustry, Apures Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apures Co's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Apures Co's Debt-to-Revenue falls into.



Apures Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Apures Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3610.362 + 2632.019) / 658.916
=9.47

Apures Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3610.362 + 2632.019) / 658.916
=9.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (Dec. 2023) Revenue data.


Apures Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apures Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines